<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548574</url>
  </required_header>
  <id_info>
    <org_study_id>SPD476-302</org_study_id>
    <nct_id>NCT00548574</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis</brief_title>
  <official_title>A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, in Subjects With Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to compare the percentage of subjects in remission
      after 8 weeks of treatment with SPD476, 2.4 g/day once daily vs placebo and SPD476 4.8 g/day
      once daily versus placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects in remission (UC-DAI score &lt;=1, with scores of 0 for rectal bleeding and stool frequency and a sigmoidoscopy score reduction of 1 point or more from baseline)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement as defined by a drop of =&gt; 3 points from baseline in the overall UC-DAI score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseine in UC-DAI score, symptoms, sigmoidscopy score, and PGA</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission defined as subjects who scored 0 for both the total stool frequency and the total rectal bleeding score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure defined as unchanged, worsened missing or imcomplete UC-DAI score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">343</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine</intervention_name>
    <other_name>LIALDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine</intervention_name>
    <other_name>ASACOL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the
             UC-DAI scale, with a sigmoidoscopy score of =&gt; 1 and a PGA &lt;=2) with compatible
             histology

          -  females eligible if post--menopausal, surgically sterile or if they had a negative
             urine pregnancy test at screening and were on adequate contraception

        Exclusion Criteria:

          -  subjects with relapsing UC who were in relapse for &gt; 6 weeks prior to baseline

          -  subjects who relapsed on maintenace therapy with doses of mesalazine =&gt; 2g/day

          -  subjects who had unsuccessfully treated their current relapse with steroids or a
             mesalazine dose of &gt; 2g/day

          -  subjects with Crohn's disease, proctitis, bleeding disorders, active peptic ulcer
             disease, previous colonic surgery, or those at an immediate risk of toxic megacolon or
             a stool culture positive for enteric pathogens

          -  subjects who had used systemic or rectal steroids within the last 4 weeks,
             immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat
             basis within 7 days prior to the baseline visit

          -  subjects with hypersensitivity to salicylates and subjects with moderate/severe renal
             impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Michael Kamm</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Marks Hospital, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imelda General Hospital Dept of Gastroenterology</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall information</description>
  </link>
  <results_reference>
    <citation>Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan;132(1):66-75; quiz 432-3. Epub 2006 Oct 12.</citation>
    <PMID>17241860</PMID>
  </results_reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2007</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

